However, mass-spectrometry based interactome measurements cannot be readily scaled to survey the entire spectrum of clinical CF variants or how they are remodeled by the growing array of clinical and emerging pre-clinical CFTR modulators. This evidence concerns the gene CFTR and cystic fibrosis.